Livforsakringsbolaget Skandia’s Charles River Laboratories CRL Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-400	Closed	-$73.8K	–	575
2024 Q4	$73.8K	Hold	400	–	–	﹤0.01%	521
2024 Q3	$78.8K	Buy	+400	New	+$83.1K	﹤0.01%	538
2023 Q4	–	Sell	-2,070	Closed	-$406K	–	578
2023 Q3	$406K	Hold	2,070	–	–	0.04%	211
2023 Q2	$435K	Hold	2,070	–	–	0.05%	217
2023 Q1	$418K	Hold	2,070	–	–	0.04%	227
2022 Q4	$451K	Hold	2,070	–	–	0.05%	220
2022 Q3	$407K	Hold	2,070	–	–	0.05%	222
2022 Q2	$443K	Hold	2,070	–	–	0.04%	244
2022 Q1	$588K	Hold	2,070	–	–	0.04%	251
2021 Q4	$780K	Buy	2,070 +870	+73%	+$338K	0.05%	231
2021 Q3	$495K	Hold	1,200	–	–	0.03%	338
2021 Q2	$444K	Buy	+1,200	New	+$401K	0.03%	373

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Livforsakringsbolaget Skandia's CRL Position: Q1 2025 in Review

Livforsakringsbolaget Skandia sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 400 shares — an estimated $73.8K sold.

Livforsakringsbolaget Skandia first reported a position in CRL in Q2 2021 and held it in 12 quarters. The position peaked at $780K in Q4 2021. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

Livforsakringsbolaget Skandia reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
Livforsakringsbolaget Skandia sold 400 Charles River Laboratories shares in Q1 2025, an estimated $73.8K.
Livforsakringsbolaget Skandia first reported a position in Charles River Laboratories in Q2 2021 and held it in 12 quarters.
Livforsakringsbolaget Skandia's Charles River Laboratories position peaked at $780K in Q4 2021.
561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Livforsakringsbolaget Skandia's 13F filing for Q1 2025, filed 15 Apr 2025.